Zhao Chengzhu, Ikeya Makoto
Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto 606-8507, Japan.
Stem Cells Int. 2018 Jul 31;2018:9601623. doi: 10.1155/2018/9601623. eCollection 2018.
Mesenchymal stem cells (MSCs) are adult stem cells with fibroblast-like morphology and isolated from the bone marrow via plastic adhesion. Their multipotency and immunoregulatory properties make MSCs possible therapeutic agents, and an increasing number of publications and clinical trials have highlighted their potential in regenerative medicine. However, the finite proliferative capacity of MSCs limits their scalability and global dissemination as a standardized therapeutic product. Furthermore, adult tissue provenance could constrain accessibility, impinge on cellular potency, and incur greater exposure to disease-causing pathogens based on the donor. These issues could be circumvented by the derivation of MSCs from pluripotent stem cells. In this paper, we review methods that induce and characterize MSCs derived from induced pluripotent stem cells (iPSCs) and introduce MSC applications to disease modeling, pathogenic mechanisms, and drug discovery. We also discuss the potential applications of MSCs in regenerative medicine including cell-based therapies and issues that should be overcome before iPSC-derived MSC therapy will be applied in the clinic.
间充质干细胞(MSCs)是具有成纤维细胞样形态的成体干细胞,通过塑料黏附从骨髓中分离得到。它们的多能性和免疫调节特性使MSCs成为可能的治疗剂,并且越来越多的出版物和临床试验突出了它们在再生医学中的潜力。然而,MSCs有限的增殖能力限制了它们作为标准化治疗产品的可扩展性和全球传播。此外,成体组织来源可能会限制可及性,影响细胞潜能,并因供体而增加接触致病病原体的风险。这些问题可以通过从多能干细胞中衍生出MSCs来规避。在本文中,我们综述了诱导和鉴定诱导多能干细胞(iPSCs)来源的MSCs的方法,并介绍了MSCs在疾病建模、致病机制和药物发现中的应用。我们还讨论了MSCs在再生医学中的潜在应用,包括基于细胞的疗法,以及在iPSC来源的MSC疗法应用于临床之前应克服的问题。